Tarsus Pharmaceuticals, Inc.
TARSNASDAQHealthcare● Active
$59.22
$-0.06(-0.10%)
Market Cap$2.5B
P/E Ratio—
52W High$85.25
52W Low$38.51
Tarsus Pharmaceuticals, Inc. (TARS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TARS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.45B | $0.18B | $0.02B | $0.03B | $0.06B |
| Cost of Revenue | $0.03B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.42B | $0.17B | $0.02B | $0.02B | $0.05B |
| Gross Margin %(computed) | 93.20% | 92.99% | 90.87% | 96.30% | 96.36% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.05B | $0.05B | $0.04B | $0.04B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.04B | $0.03B |
| Total Operating Expenses | $0.49B | $0.29B | $0.16B | $0.09B | $0.07B |
| Operating Income | ($0.07B) | ($0.12B) | ($0.14B) | ($0.06B) | ($0.01B) |
| Operating Margin %(computed) | -15.72% | -65.90% | -820.53% | -242.92% | -21.32% |
| Interest Income | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.06B) | ($0.12B) | ($0.14B) | ($0.06B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Net Income | ($0.07B) | ($0.12B) | ($0.14B) | ($0.06B) | ($0.01B) |
| Net Margin %(computed) | -14.72% | -63.16% | -778.89% | -240.51% | -24.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.03B | 0.02B | 0.02B |
| EBITDA | ($0.05B) | ($0.11B) | ($0.13B) | ($0.06B) | ($0.01B) |
| EBITDA Margin %(computed) | -11.88% | -58.20% | -754.69% | -231.27% | -23.60% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Tarsus Pharmaceuticals, Inc. data
About Tarsus Pharmaceuticals, Inc. (TARS) Income Statement
Tarsus Pharmaceuticals, Inc. (TARS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TARS reported revenue of $0.45B, gross profit of $0.42B (gross margin 93.20%), and net income of ($0.07B) — a net profit margin of -14.72%.
Frequently asked questions
TARS · 4 questionsTarsus Pharmaceuticals, Inc. (TARS) reported revenue of $0.45B for 2025, up 146.7% year-over-year.
TARS revenueTARS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08